Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Korábbi kezelés

• Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Grade ≥2 from previous anticancer therapy.
• Active or prior documented GI bleeding.

Más betegség

• History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy.
• Patients with main portal vein thrombosis.
• Patient currently exhibits symptomatic or uncontrolled hypertension.
• Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV)
• Uncontrolled intercurrent illness

Egyéb

• Clinically meaningful ascites.

• Confirmed HCC based on histopathological findings from tumor tissues or radiologically findings.
• Must not have received prior systemic therapy for unresectable HCC.
• Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.
• Child-Pugh Score class A.
• ECOG performance status of 0 or 1 at enrollment.
• At least 1 measurable lesion per RECSIT 1.1 guidelines